Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer.
BACKGROUND
The aim of this study was to evaluate the significance of nuclear factor-kappa B (NF-kappaB) expression as a marker of radioresistance in early-stage laryngeal cancer.


METHODS
Thirty-five patients with local recurrence and 70 case-matched patients without local recurrence were entered in this study. NF-kappaB expression was compared with Bcl-2 and epidermal growth factor (EGF) receptor expression by immunohistochemistry, using pretreatment biopsy specimens. The prognostic value of NF-kappaB was also evaluated. Twenty-nine recurrent tumors were compared with pretreatment tumors.


RESULTS
NF-kappaB expression in pretreatment tumors significantly correlated with local tumor control (p = .01), but bcl-2 and EGF receptor expression did not. Only NF-kappaB expression showed prognostic significance for local tumor control in both univariate and multivariate analyses (p = .008 and .04, respectively). NF-kappaB expression was markedly enhanced in 23 of 29 (80%) recurrent tumors.


CONCLUSIONS
NF-kappaB expression may be a novel marker of radioresistance in early-stage laryngeal cancer.
Yoshida
Kenji
K
Division of Radiation Oncology, Kobe University Graduate School of Medicine, Hyogo, Japan.
Sasaki
Ryohei
R
Nishimura
Hideki
H
Okamoto
Yoshiaki
Y
Suzuki
Yoko
Y
Kawabe
Tetsuya
T
Saito
Miki
M
Otsuki
Naoki
N
Hayashi
Yoshitake
Y
Soejima
Toshinori
T
Nibu
Kenichi
K
Sugimura
Kazuro
K
D014408:Biomarkers, Tumor / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D016022:Case-Control Studies; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011836:Radiation Tolerance
D014408:Biomarkers, Tumor; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D066246:ErbB Receptors